Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer.
Cancer Chemother Pharmacol
; 85(3): 487-499, 2020 03.
Article
in En
| MEDLINE
| ID: mdl-31768697
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Biosimilar Pharmaceuticals
/
Bevacizumab
/
Antineoplastic Agents, Immunological
/
Lung Neoplasms
Type of study:
Clinical_trials
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Cancer Chemother Pharmacol
Year:
2020
Type:
Article
Affiliation country:
United States